At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 14, 2026 at 09:15 ET
Biogen announced Phase 2 CELIA data for diranersen, an anti-tau ASO, showing clinical slowing on CDR-SB (26% at 60 mg) and robust CSF tau reduction (50-65%). The study missed its primary endpoint (dose response on CDR-SB), but the totality of biomarker and cognitive data provides proof of concept, and Biogen plans to advance to Phase 3.
- Phase 2 CELIA study of diranersen in early Alzheimer's disease: 416 participants, 18-month placebo-controlled period.
- Primary endpoint (dose response on CDR-SB) was not met; higher doses did not show greater slowing.
- 60 mg dose showed 26% slowing on CDR-SB, 42% on ADAS-Cog13, 50% on MMSE vs placebo; nominal statistical significance on most endpoints.
- CSF total tau reduced 50-65% across all doses; first tau-directed therapy to show reductions in both CSF tau and brain tau PET.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access